REICH SIEGFRIED (EVP & Chief Scientific Officer) sold 10.3% of their position (397.00 shares) of TURNING POINT THERAPEUTICS, INC. on the open market
Open‑market sale worth $14.4K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/11/2022ACC: 0001209191-22-008984
Officer· EVP & Chief Scientific Officer
Since Mar 2020
+62K
Net shares
Net buyer
$14.4K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
62.40K acquired · 397.00 disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−397.00
Price / share
$36.30
Trade value
$14.41K
% of position
10.3%
2/9/2022
3.85K→3.45K
Common Stock
Direct
Shares
+13.57K
Price / share
—
Trade value
—
% of position
393.5%
2/9/2022
3.45K→17.02K
Total
Net shares
+13.17K
Net value
-$14.41K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/9/2022 | S · Sale | −397.00 | $36.30 | $14.41K | 10.3% | 3.85K | 3.45K |
| Common Stock Direct | 2/9/2022 | A · Award | +13.57K | — | — | 393.5% | 3.45K | 17.02K |
| Total | +13.17K | -$14.41K | ||||||
Derivative Transactions1
Stock Option (right to buy)
Direct
Converts to
Common Stock
48.83K shares
Shares
+48.83K
Strike price
37.68
Held after
48.83K
Exercisable
—
2/9/2022
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock48.83K shares | 2/9/2022 | A · Award | +48.83K | 37.68 | — | 48.83K |